Trial | NCT00032929  Report issue

Title

Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1
Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    selegiline ...

  • Study Participants

    269
The purpose of this study is to evaluate the Selegiline Transdermal System for the treatment of cocaine dependence.
The study objectives are to assess the efficacy and safety of the Selegiline Transdermal System (STS) in reducing cocaine use in subjects with cocaine dependence. It is hypothesized that selegiline treatment compared to placebo, will be associated with fewer days of cocaine use as assessed by self-report confirmed with urine assays for benzoylecgonine (BE).
Study Started
Mar 31
2001
Primary Completion
Dec 31
2002
Last Update
Jan 12
2017
Estimate

Drug Selegiline

Criteria 

Inclusion Criteria:

Male/Female
At least 18 years of age
DSM-4 diagnosis of cocaine dependence
Ability to understand and provide written consent
Female subjects must use acceptable birth control

Exclusion Criteria:

- Additional Criteria available during the screening process at the site.
No Results Posted